Quarterly report · Q1
3151.TEDINET S100RLIV
Period2023-04-01 → 2023-06-30
Filed2023-08-09
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥144.5bn | 2023-04-01 → 2023-06-30 | Cons. | Net sales |
| Revenue | ¥581.3bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥143.9bn | 2022-04-01 → 2022-06-30 | Cons. | Net sales |
| Operating income | ¥1.2bn | 2023-04-01 → 2023-06-30 | Cons. | Operating income |
| Operating income | ¥849m | 2022-04-01 → 2022-06-30 | Cons. | Operating income |
| Ordinary income | ¥1.5bn | 2023-04-01 → 2023-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥6.0bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.2bn | 2022-04-01 → 2022-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥1.4bn | 2023-04-01 → 2023-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥1.1bn | 2022-04-01 → 2022-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥917m | 2023-04-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥4.8bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥640m | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥945m | 2023-04-01 → 2023-06-30 | Cons. | Profit loss |
| Net income | ¥675m | 2022-04-01 → 2022-06-30 | Cons. | Profit loss |
| Total assets | ¥305.7bn | at 2023-06-30 | Cons. | Assets |
| Total assets | ¥297.3bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥314.2bn | at 2022-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥203.5bn | at 2023-06-30 | Cons. | Liabilities |
| Total liabilities | ¥197.2bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥102.2bn | at 2023-06-30 | Cons. | Net assets |
| Net assets / equity | ¥100.2bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥101.4bn | at 2022-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥21.4bn | at 2023-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥19.0bn | at 2023-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥17.81 | 2023-04-01 → 2023-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥92.69 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥12.05 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 33.0% | at 2023-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.3% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 31.9% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 54
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2023-06-30 | ¥1.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2023-06-30 | ¥1.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥648m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2023-06-30 | −¥90m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-06-30 | −¥3.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-06-30 | −¥3.4bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-06-30 | ¥15m |
| jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥138.7bn |
| jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥135.9bn |
| jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥2.8bn |
| jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥1.1bn |
| jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥4.7bn |
| jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥4.7bn |
| jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥3m |
| jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥87m |
| jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥2.8bn |
| jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥2.8bn |
| jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥0 |
| jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥99m |
| —segment total | revenue | 2023-04-01 → 2023-06-30 | ¥146.1bn |
| —segment total | revenue external | 2023-04-01 → 2023-06-30 | ¥143.4bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥2.8bn |
| —segment total | segment profit | 2023-04-01 → 2023-06-30 | ¥1.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-06-30 | ¥148.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-06-30 | ¥144.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥3.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-06-30 | ¥1.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-06-30 | ¥1.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-06-30 | ¥1.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥626m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-06-30 | −¥69m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-06-30 | −¥3.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-06-30 | −¥3.4bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-06-30 | ¥0 |
| jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥138.4bn |
| jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥135.6bn |
| jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥2.8bn |
| jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥783m |
| jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥4.5bn |
| jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥4.5bn |
| jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥0 |
| jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥14m |
| jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥2.7bn |
| jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥2.7bn |
| jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥0 |
| jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥121m |
| —segment total | revenue | 2022-04-01 → 2022-06-30 | ¥145.5bn |
| —segment total | revenue external | 2022-04-01 → 2022-06-30 | ¥142.7bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥2.8bn |
| —segment total | segment profit | 2022-04-01 → 2022-06-30 | ¥919m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-06-30 | ¥147.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-06-30 | ¥143.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥3.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-06-30 | ¥850m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 362
| Item | Context | Value | Unit |
|---|---|---|---|
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Disclosure of changes etc in reportable segments (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |